Diagnos (ADK.V) said Thursday it received marketing authorization for its CARA System of AI-driven retinal image analysis from the Saudi Food and Drug Authority (SFDA).
The version of CARA licensed in Saudi Arabia includes detection algorithms for diabetic retinopathy and age-related macular degeneration, a statement said.
Diagnos is working with a local distributor in Saudi Arabia to market the device.
The company's shares were last seen up C$0025 to C$0.41 on the TSX Venture Exchange.
Price: $0.41, Change: $+0.03, Percent Change: +6.49%